Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P33527 (
ABCC1
)
1,164
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Osteosarcoma (OS) is the most common primary malignant bone cancer in children and adolescents. Long non-coding RNAs (lncRNAs) have been shown to play significant role in various cancers, including OS. In a previous study, we have reported that a novel antisense lncRNA
FOXF1
-AS1, also known as FENDRR, could sensitize doxorubicin-resistance of OS cells through down-regulating ABCB1 and
ABCC1
. Here in, the critical role of
FOXF1
-AS1 in regulating OS progression was further investigated. Firstly, we found that
FOXF1
-AS1 and its antisense transcript
FOXF1
expression were positively up-regulated in OS tissues and cell lines and correlated with poor prognosis of OS patients. Besides,
FOXF1
-AS1 as well as
FOXF1
silencing significantly inhibited cell proliferation, migration, invasion of OS cells and tumor growth both
in vitro
and
vivo
through decreasing the expression of MMP2 and MMP9, whereas enhanced expression of
FOXF1
-AS1 had the opposite effects. In addition, mechanistically, both of
FOXF1
-AS1 and
FOXF1
could regulate the expression of MMP2 and MMP9 at mRNA and protein levels, whereas
FOXF1
-AS1 could influence the FOXF1expression but
FOXF1
did not have the same effect on
FOXF1
-AS1. Rescue assay further showed that
FOXF1
-AS1 overexpression efficiently reversed the knockdown of MMP2 and MMP9 expression induced by si-
FOXF1
. Thus, we concluded that
FOXF1
-AS1 may promote migration and invasion of OS cells through the
FOXF1
/MMP-2/-9 pathway. Taken together, these findings demonstrated the underlying mechanism of
FOXF1
-AS1 in the regulation of OS progression and provide a novel potential target in the OS therapy.
...
PMID:Antisense lncRNA FOXF1-AS1 Promotes Migration and Invasion of Osteosarcoma Cells Through the FOXF1/MMP-2/-9 Pathway. 2910 9